Option Care Health, Inc. $OPCH Shares Acquired by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. lifted its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 25.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 110,992 shares of the company’s stock after purchasing an additional 22,536 shares during the period. Johnson Investment Counsel Inc. owned approximately 0.07% of Option Care Health worth $3,081,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of OPCH. Royal Bank of Canada increased its stake in Option Care Health by 20.7% in the 1st quarter. Royal Bank of Canada now owns 231,161 shares of the company’s stock worth $8,078,000 after purchasing an additional 39,661 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Option Care Health by 162.6% in the first quarter. AQR Capital Management LLC now owns 41,633 shares of the company’s stock worth $1,450,000 after buying an additional 25,777 shares during the period. Empowered Funds LLC purchased a new position in shares of Option Care Health in the first quarter worth approximately $208,000. Blair William & Co. IL raised its holdings in shares of Option Care Health by 67.9% during the second quarter. Blair William & Co. IL now owns 78,693 shares of the company’s stock valued at $2,556,000 after acquiring an additional 31,821 shares during the period. Finally, Blue Trust Inc. raised its holdings in shares of Option Care Health by 23.0% during the second quarter. Blue Trust Inc. now owns 6,495 shares of the company’s stock valued at $211,000 after acquiring an additional 1,213 shares during the period. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Price Performance

OPCH opened at $33.15 on Wednesday. The stock has a fifty day moving average price of $33.32 and a 200 day moving average price of $30.06. The company has a current ratio of 1.56, a quick ratio of 1.05 and a debt-to-equity ratio of 0.85. Option Care Health, Inc. has a 1 year low of $24.24 and a 1 year high of $36.80. The stock has a market cap of $5.26 billion, a price-to-earnings ratio of 26.31, a PEG ratio of 1.98 and a beta of 0.84.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Option Care Health from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Barrington Research lifted their price target on Option Care Health from $38.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, January 16th. Stephens raised Option Care Health to a “strong-buy” rating in a research report on Thursday, December 11th. Citigroup restated an “outperform” rating on shares of Option Care Health in a research report on Tuesday, January 13th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $37.00 target price on shares of Option Care Health in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Option Care Health has an average rating of “Moderate Buy” and a consensus price target of $37.46.

Option Care Health Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.